Genmab — November 2018

kkjoel

Will MorphoSys win the Darzalex patent case against Janssen and Genmab? — Markman Advisors

In 2016, MorphoSys ($MOR) sued Janssen ($JNJ) and Genmab for patent infringement. MorphoSys claims that Janssen’s anti-CD38 antibody, Darzalex®, infringes three of its patents. The case is scheduled to go to trial in February 2019. The stakes are big because the patents purport to cover the actual protein used in Darzalex®, which could mean material royalty rates on sales of Janssen’s drug. What are the strengths and weaknesses of each party’s case?

Markman Advisors (www.markmanadvisors.com)

kkjoel

Altså sådan i lovtermer/juraslang.

bibob

Blev linket i går kkjoel.

kkjoel

Ok.

gentogen

Nu er jeg jo selvfølgelig forudindtaget, men det virker j ret afslørende, at Morphosys angiveligt har forsøgt at hindre juryen i at få oplyst, at Morphosys i deres oprindelige patentansøgning slet ikke havde fremstillet de antibodies, som de påstod...

Legolas23

Præcis. De mener, de har søgt patent på en virkning, de havde til hensigt at opfinde, men endnu ikke var i besiddelse af.

kkjoel

Svaret fra Rachel: "As you say, yesterday there was held a summary judgement hearing. However, nothing was decided at the hearing, the judge heard the arguments but has not yet given a ruling. With the regard to yesterday’s proceedings. We were pleased with the outcome of the court hearing. With one exception, the court denied all of MorpohoSys’s motions, including motions to exclude evidence from trial and for judgment on certain claims.

kkjoel

The only MorphoSys motion that was granted was simply entering judgment on infringement of certain patent claims that we had already stipulated to several months ago (under the court’s current claim construction to which we continue to disagree and to which we have the right to appeal), but to which we believe we have very strong invalidity defenses.

kkjoel

In contrast, the court did not rule on Janssen and Genmab’s motions to invalidate the asserted patents, and a decision would be expected in the next two months. Should the case be halted for any reason we would, as covered by our disclosure obligations, issue a company announcement concerning the outcome. Otherwise, the case would continue as planned to a jury trail in February next year."

JKY_VH

tak kkjoel

kkjoel

Korte version: Der er ikke kommet nogen dom endnu, så det kan stadig komme til retssag i feb. 2019. Men som man kan læse har GEN tilsyneladende en stærk case.